Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-09-17 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : EADV : Les résultats de l’étude de phase 2a montrent que le brivekimig de Sanofi est efficace dans le traitement de l’hidrosadénite suppurée
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing positive clinical trial results (Phase 2a) for a drug candidate (brivekimig). It details the study methodology, efficacy results (HiSCR50, HiSCR75, HiSCR90), and safety data. This type of document, which provides updates on research and development progress and clinical trial outcomes, is classified as a Regulatory Filing (RNS) in the absence of a more specific 'Clinical Trial Results' category, as it serves as a general corporate announcement regarding company operations and R&D milestones.
2025-09-17 French
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing positive clinical trial results (Phase 2a) for a drug candidate (brivekimig). It details study methodology, primary and secondary endpoints, and safety data. It does not fit into financial reporting categories like 10-K or IR, nor is it a regulatory filing or a report publication announcement. In the context of pharmaceutical companies, announcements of clinical trial results are standard corporate communications that fall under the 'Regulatory Filings' (RNS) category as a general regulatory announcement, as there is no specific 'Clinical Trial Results' category provided in the schema.
2025-09-17 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled 'Déclaration des transactions sur actions propres' (Declaration of transactions in own shares) and provides a detailed log of share repurchases by Sanofi, including dates, volumes, prices, and transaction identifiers. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-09-15 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is a formal disclosure by Sanofi regarding the purchase of its own shares (share buyback) over a specific period (08 September 2025 to 12 September 2025). It includes aggregated daily data and a detailed transaction-by-transaction log, which is the standard format for 'Transaction in Own Shares' filings under market abuse regulations (MAR).
2025-09-15 English
Sanofi: Information concerning the total number of voting rights and shares - August 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal disclosure of the total number of voting rights and shares, as required by French regulatory articles (L. 233-8 II of the Code de commerce). This type of disclosure is a standard regulatory requirement for publicly traded companies in France to inform the market of their share capital structure and voting rights. It does not constitute a shareholder vote result (DVA), a major shareholding notification (MRQ), or a share buyback (POS), but rather a periodic regulatory update on share capital status.
2025-09-12 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions - AOUT 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a standard French regulatory disclosure regarding the total number of voting rights and shares, as required by Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. This type of filing is a routine regulatory announcement concerning share capital and voting rights, which does not fit into specific categories like 'Share Issue' (SHA) or 'Major Shareholding' (MRQ) as it is a periodic disclosure of the company's own capital structure. Therefore, it is classified as a Regulatory Filing (RNS).
2025-09-12 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.